Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 8/20 | 0.46 |
| ▸ | CPA1 | P15085 | 5/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22810961 | 1.00 | POLB (0.49) | POLBACEALDH1A1HSD17B10MME | |
| SCHEMBL9892967 | 1.00 | POLB (0.49) | POLBACEALDH1A1HSD17B10MME | |
| SCHEMBL21699252 | 1.00 | POLB (0.49) | POLBACEALDH1A1HSD17B10MME | |
| SCHEMBL15313443 | 1.00 | POLB (0.49) | POLBACEALDH1A1HSD17B10MME | |
| SCHEMBL18912329 | 0.93 | GAA (0.54) | POLBALDH1A1HSD17B10GAALMNA | |
| SCHEMBL19647312 | 0.93 | GAA (0.54) | POLBALDH1A1HSD17B10GAALMNA | |
| SCHEMBL22600820 | 0.90 | NPC1 (0.44) | ACEMMEGAALMNAKMT2A | |
| SCHEMBL26765974 | 0.90 | NPC1 (0.44) | ACEMMEGAALMNAKMT2A | |
| SCHEMBL22476513 | 0.89 | GAA (0.42) | ACEALDH1A1HSD17B10GAA | |
| SCHEMBL2755704 | 0.89 | ALDH1A1 (0.52) | POLBACEALDH1A1HSD17B10MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088378-B2 | Anti-CD79B antibodies and immunoconjugates and methods of use | GENETECH INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088378-B2 | Anti-CD79B antibodies and immunoconjugates and methods of use | GENETECH INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | GENENTECH, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | GENENTECH, INC. (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | CD99, CD79B, CD47 | POLB 1320/4885ACE 4864/4885ALDH1A1 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.